JP2025513850A5 - - Google Patents
Info
- Publication number
- JP2025513850A5 JP2025513850A5 JP2024560404A JP2024560404A JP2025513850A5 JP 2025513850 A5 JP2025513850 A5 JP 2025513850A5 JP 2024560404 A JP2024560404 A JP 2024560404A JP 2024560404 A JP2024560404 A JP 2024560404A JP 2025513850 A5 JP2025513850 A5 JP 2025513850A5
- Authority
- JP
- Japan
- Prior art keywords
- capsid
- irak
- pharmaceutical composition
- aav
- viral vector
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263330239P | 2022-04-12 | 2022-04-12 | |
| US63/330,239 | 2022-04-12 | ||
| PCT/US2023/065687 WO2023201272A1 (en) | 2022-04-12 | 2023-04-12 | Use of irak4 modulators for gene therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2025513850A JP2025513850A (ja) | 2025-04-30 |
| JP2025513850A5 true JP2025513850A5 (enExample) | 2026-04-20 |
Family
ID=86329443
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024560404A Pending JP2025513850A (ja) | 2022-04-12 | 2023-04-12 | 遺伝子治療のためのｉｒａｋ４モジュレーターの使用 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230405151A1 (enExample) |
| EP (1) | EP4508225A1 (enExample) |
| JP (1) | JP2025513850A (enExample) |
| KR (1) | KR20250004740A (enExample) |
| CN (1) | CN119630802A (enExample) |
| AU (1) | AU2023252915A1 (enExample) |
| CA (1) | CA3248481A1 (enExample) |
| IL (1) | IL316231A (enExample) |
| MX (1) | MX2024012616A (enExample) |
| TW (1) | TW202400250A (enExample) |
| WO (1) | WO2023201272A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CA3161878A1 (en) | 2019-12-17 | 2021-06-24 | Matthew M. Weiss | Irak degraders and uses thereof |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2264482A1 (en) | 1996-09-06 | 1998-03-12 | The Trustees Of The University Of Pennsylvania | An inducible method for production of recombinant adeno-associated viruses utilizing t7 polymerase |
| US6995006B2 (en) | 1997-09-05 | 2006-02-07 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6566118B1 (en) | 1997-09-05 | 2003-05-20 | Targeted Genetics Corporation | Methods for generating high titer helper-free preparations of released recombinant AAV vectors |
| US6596535B1 (en) | 1999-08-09 | 2003-07-22 | Targeted Genetics Corporation | Metabolically activated recombinant viral vectors and methods for the preparation and use |
| US6818419B2 (en) | 2000-01-13 | 2004-11-16 | Tularik Inc. | IRAK-4: compositions and methods of use |
| US7465583B2 (en) | 2000-06-01 | 2008-12-16 | The University Of North Carolina At Chapel Hill | Duplexed parvovirus vectors |
| US7510872B2 (en) | 2003-02-26 | 2009-03-31 | Nationwide Children's Hospital | Recombinant adeno-associated virus production |
| JP4559429B2 (ja) | 2003-05-21 | 2010-10-06 | ジェンザイム・コーポレーション | 空キャプシドを実質的に含まない組換えａａｖビリオン調製物を生成するための方法 |
| US20100279316A1 (en) | 2007-01-19 | 2010-11-04 | Leonid Gorelik | Antibodies to Phosphorylated IRAK4 |
| JP5956331B2 (ja) | 2009-06-16 | 2016-07-27 | ジェンザイム・コーポレーション | 組換えａａｖベクターの改良された精製方法 |
| US20110070241A1 (en) * | 2009-06-30 | 2011-03-24 | Duke University | Methods for modulating immune responses to aav gene therapy vectors |
| DK2561073T3 (en) | 2010-04-23 | 2016-12-12 | Univ Massachusetts | Aav vectors targeted to central nervous system and methods of use thereof |
| JP2017513954A (ja) | 2014-04-22 | 2017-06-01 | ニンバス アイリス， インコーポレイテッド | Ｉｒａｋ阻害剤およびその使用 |
| EP3200788B1 (en) | 2014-09-30 | 2019-09-18 | Merck Sharp & Dohme Corp. | Inhibitors of irak4 activity |
| US10040798B2 (en) | 2015-03-12 | 2018-08-07 | Merck Sharp & Dohme Corp. | Pyrrolopyridazine inhibitors of IRAK4 activity |
| WO2017004133A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| EP3322409A4 (en) | 2015-07-15 | 2019-07-24 | Aurigene Discovery Technologies Limited | SUBSTITUTED AZA COMPOUNDS AS IRAQ-4 INHIBITORS |
| CN107531725B (zh) | 2015-08-13 | 2021-03-19 | 北京韩美药品有限公司 | Irak4抑制剂及其应用 |
| CN110234637B (zh) | 2016-10-26 | 2022-11-01 | 里格尔药品股份有限公司 | 用作irak抑制剂的吡唑酰胺化合物 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| CA3090275A1 (en) | 2018-02-14 | 2019-08-22 | Dana-Farber Cancer Institute, Inc. | Irak degraders and uses thereof |
| EP3774797B1 (en) | 2018-04-05 | 2025-11-19 | Merck Patent GmbH | Heteroaryl compounds as type ii irak inhibitors and uses hereof |
| EP3814380A4 (en) | 2018-06-29 | 2022-06-15 | Dana Farber Cancer Institute, Inc. | BISPECIFIC DEGRADATION PRODUCTS |
| AU2019389174A1 (en) | 2018-11-30 | 2021-07-01 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| WO2020264490A1 (en) | 2019-06-28 | 2020-12-30 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| US12558427B2 (en) | 2019-07-17 | 2026-02-24 | Kymera Therapeutics, Inc. | IRAK degraders and uses thereof |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| JP7815127B2 (ja) | 2020-02-19 | 2026-02-17 | ニューリックス セラピューティクス，インコーポレイテッド | インターロイキン－１受容体関連キナーゼの二機能性分解剤およびその治療的使用 |
| EP4149622A4 (en) * | 2020-05-12 | 2024-12-18 | Myogene Bio LLC | IMMUNOSUPPRESSIVE AGENTS AND METHODS OF RE-DOSING VIRAL ADMINISTRATION FOR GENE THERAPY |
| EP4161521A4 (en) | 2020-06-03 | 2024-07-10 | Kymera Therapeutics, Inc. | DEUTERED IRAQ DEGRADERS AND USES THEREOF |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
-
2023
- 2023-04-12 CN CN202380043587.1A patent/CN119630802A/zh active Pending
- 2023-04-12 JP JP2024560404A patent/JP2025513850A/ja active Pending
- 2023-04-12 TW TW112113694A patent/TW202400250A/zh unknown
- 2023-04-12 KR KR1020247037276A patent/KR20250004740A/ko active Pending
- 2023-04-12 AU AU2023252915A patent/AU2023252915A1/en active Pending
- 2023-04-12 EP EP23722239.3A patent/EP4508225A1/en active Pending
- 2023-04-12 IL IL316231A patent/IL316231A/en unknown
- 2023-04-12 US US18/299,632 patent/US20230405151A1/en active Pending
- 2023-04-12 WO PCT/US2023/065687 patent/WO2023201272A1/en not_active Ceased
- 2023-04-12 CA CA3248481A patent/CA3248481A1/en active Pending
-
2024
- 2024-10-10 MX MX2024012616A patent/MX2024012616A/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20210285012A1 (en) | Method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby | |
| CN108602859B (zh) | 增强细小病毒载体递送的修饰衣壳蛋白 | |
| CN102174574B (zh) | 腺伴随病毒(aav)进化支、序列、含有这些序列的载体及它们的应用 | |
| US20220280655A1 (en) | New Adeno-Associated Virus (AAV) Variants and Uses Thereof for Gene Therapy | |
| TW201629225A (zh) | 第九因子基因療法 | |
| JP2022545121A (ja) | Ａａｖ５の単離修飾ｖｐ１カプシドタンパク質 | |
| JP2025513851A5 (enExample) | ||
| CN111876432B (zh) | 一组肝靶向新型腺相关病毒的获得及其应用 | |
| TW202402329A (zh) | Irak4調節劑於基因療法之用途(二) | |
| US11077208B2 (en) | Wilson's disease gene therapy | |
| TW202405430A (zh) | 對於基因療法藥劑的先天免疫原性之樹突細胞試驗 | |
| JP2023513932A (ja) | Ｘ連鎖障害の治療におけるｍｉＲＮＡのＡＡＶ媒介標的化 | |
| RU2024133631A (ru) | Применение модуляторов irak4 для генной терапии | |
| CA2756866E (en) | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby | |
| Еpifanova et al. | Viral Vectors for Delivering Gene Material into Cells and Their Application in Neurobiology | |
| EA050477B1 (ru) | Доставка альфа-саркогликана с помощью вектора на основе аденоассоциированного вируса и лечение мышечной дистрофии | |
| HU230093B1 (hu) | Eljárás adeno-asszociált vírus(AAV)szekvenciák detektálására és/vagy azonosítására, és az azzal azonosított új szekvenciák izolálására | |
| HK1068925B (en) | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby | |
| HK1260937B (en) | Modified capsid proteins for enhanced delivery of parvovirus vectors |